Dr. Dalia Megiddo is an experienced life-science and investment professional in the pharmaceutical and healthcare sectors. She has co-founded and served on the Board of Directors for a number of pharmaceutical companies, including Alcobra Ltd. (Nasdaq: ADHD) and Chiasma Ltd. (Nasdaq: CHMA). She currently serves as Managing Partner of Expedio Ventures, and previously ran other life science investment funds, including Jerusalem Global Ventures - InnoMed and 7-Health. Dr. Megiddo also co-founded Bioblast-Pharma Ltd. (Nasdaq: ORPN) and currently serves as a member of the company’s Board of Directors. Dr. Megiddo holds an M.D. in Medicine from Hebrew University, Jerusalem, and is a licensed specialist in family medicine. She also holds an M.B.A. degree from the Kellogg Recanati International School of Business (Tel Aviv University and North Western University).